Latham & Watkins represented the underwriters in the offering.Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address…
Eliem Therapeutics’ $80 Million Initial Public Offering
